UNSPSC 51362801: Methaqualone

This classification denotes a sedative and hypnotic with the molecular formula C16H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZKH8MQW6T, chemically known as 3,4-dihydro-2-methyl-4-oxo-3-o-tolylquinazoline but generally known as methaqualone, which bears US NIH Compound Identifier 6292. European Medicines Agency schedules Methaqualone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08840MIG.

UNSPSC 51362801 Methaqualone is a Commodity code that nominally addresses a specific controlled substance, but recent state and local procurement activity tagged under this code does not reflect methaqualone procurement. Instead, the opportunities show state and local bodies acquiring naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and exploring direct-to-manufacturer prescription programs. The actual purchasing under this code reflects emergency-response health supplies, pharmacy benefit management, and pharmaceutical distribution rather than the narrow chemical category the code name suggests. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering programs on behalf of state and local members.

Activity is geographically dispersed across Florida (Seminole County), Texas (Health and Human Services Commission), and Minnesota (MMCAP representing multiple participating jurisdictions including Oregon). Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with an IFB response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, issued January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026. The code shows fragmented activity across health procurement platforms rather than concentrated demand, with mismatch between the code's nominal scope and actual purchasing patterns suggesting possible tagging errors or legacy classification.